2022
Technical Dissonance in Home Blood Pressure Monitoring After Stroke: Having the Machine, but Not Using Correctly.
Forman R, Viscoli C, Meurer K, Sheth K, Sansing L, de Havenon A, Sharma R, Mariscal M, Kernan W. Technical Dissonance in Home Blood Pressure Monitoring After Stroke: Having the Machine, but Not Using Correctly. American Journal Of Hypertension 2022, 36: 195-200. PMID: 36520024, PMCID: PMC10016067, DOI: 10.1093/ajh/hpac129.Peer-Reviewed Original ResearchConceptsHome blood pressure monitoringBlood pressure monitoringBlood pressurePressure monitoringNon-Hispanic white patientsProportion of patientsCross-sectional studyNon-Hispanic white participantsStroke recurrenceRate of useMost patientsPrimary outcomeWhite patientsRate of possessionPatientsUnderrepresented patientsArm cuffHypertensionStrokeCorrect useWhite participantsSignificant disparitiesEthnic groupsParticipantsQuality of technique
2021
Admission Hemoglobin Levels Are Associated With Functional Outcome in Spontaneous Intracerebral Hemorrhage
Acosta JN, Leasure AC, Kuohn LR, Both CP, Petersen NH, Sansing LH, Matouk CC, Testai F, Langefeld CD, Woo D, Kamel H, Murthy SB, Qureshi A, Mayer SA, Sheth KN, Falcone GJ. Admission Hemoglobin Levels Are Associated With Functional Outcome in Spontaneous Intracerebral Hemorrhage. Critical Care Medicine 2021, 49: 828-837. PMID: 33591003, PMCID: PMC8611893, DOI: 10.1097/ccm.0000000000004891.Peer-Reviewed Original ResearchConceptsAdmission hemoglobin levelsHemoglobin levelsNontraumatic intracerebral hemorrhageIntracerebral hemorrhageHematoma volumePoor outcomeHematoma expansionIntracerebral hemorrhage patientsPredictors of outcomeSpontaneous intracerebral hemorrhageIndividual patient dataHigher hemoglobin levelsAdmission hematoma volumeExposure of interestDose-response analysisAdmission hemoglobinRankin ScalePrimary outcomeHemorrhage patientsFunctional outcomeRepeat CTClinical trialsObservational studyHemorrhage sizeBetter outcomes
2020
Cause of death in spontaneous intracerebral hemorrhage survivors: Multistate longitudinal study.
Kuohn LR, Leasure AC, Acosta JN, Vanent K, Murthy SB, Kamel H, Matouk CC, Sansing LH, Falcone GJ, Sheth KN. Cause of death in spontaneous intracerebral hemorrhage survivors: Multistate longitudinal study. Neurology 2020, 95: e2736-e2745. PMID: 32917797, PMCID: PMC7734723, DOI: 10.1212/wnl.0000000000010736.Peer-Reviewed Original ResearchConceptsCause of deathRecurrent intracranial hemorrhageIntracerebral hemorrhage survivorsAtrial fibrillationICH survivorsIschemic strokeIntracranial hemorrhageSpontaneous intracerebral hemorrhage survivorsMultivariable Cox proportional hazardsCox proportional hazardsLong-term survivalMedian followRespiratory failureHospital readmissionPrimary outcomePrimary diagnosisSpontaneous ICHCardiac diseaseClaims dataMultinomial logistic regressionNontraumatic ICHProportional hazardsAdult survivorsLogistic regressionPatients
2019
Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes
Murthy SB, Biffi A, Falcone GJ, Sansing LH, Torres Lopez V, Navi BB, Roh DJ, Mandava P, Hanley DF, Ziai WC, Kamel H, Rosand J, Sheth KN, Butcher K, Davis S, Gregson B, Lees K, Lyden P, Mayer S, Muir K, Steiner T. Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes. Stroke 2019, 50: 3057-3063. PMID: 31895618, PMCID: PMC6941441, DOI: 10.1161/strokeaha.119.025972.Peer-Reviewed Original ResearchConceptsAntiplatelet therapyIntracerebral hemorrhageFunctional outcomeHematoma locationCause mortalityMajor disabilityVirtual International Stroke Trials Archive databaseCox proportional regression analysisConclusions Antiplatelet therapyRecurrent intracerebral hemorrhageProportional regression analysisPoor functional outcomeRandomized clinical trialsSpontaneous intracerebral hemorrhagePaucity of dataAntiplatelet medicationsStroke RegistryThromboembolic riskHazard ratioMulticenter cohortPrimary outcomeMedian timeICH patientsClinical trialsMeta-analyzed dataSurgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure
Awad I, Polster S, Carrión-Penagos J, Thompson R, Cao Y, Stadnik A, Money P, Fam M, Koskimäki J, Girard R, Lane K, McBee N, Ziai W, Hao Y, Dodd R, Carlson A, Camarata P, Caron J, Harrigan M, Gregson B, Mendelow A, Zuccarello M, Hanley D, Abdul-Rahim A, Abou-Hamden A, Abraham M, Ahmed A, Alba C, Aldrich E, Ali H, Altschul D, Amin-Hanjani S, Anderson C, Anderson D, Ansari S, Antezana D, Ardelt A, Arikan F, Avadhani R, Baguena M, Baker A, Barrer S, Barzo P, Becker K, Bergman T, Betz J, Bistran-Hall A, Boström A, Braun J, Brindley P, Broaddus W, Brown R, Buki A, Bulters D, Cao B, Carhuapoma J, Chalela J, Chang T, Chicoine M, Chorro I, Chowdhry S, Cobb C, Corral L, Csiba L, Davies J, Dawson J, Díaz A, Dierdeyn C, Diringer M, Dlugash R, Ecker R, Economas T, Enriquez P, Ezer E, Fan Y, Feng H, Franz D, Freeman W, Fusco M, Galicich W, Gandhi D, Gelea M, Goldstein J, Gonzalez A, Grabarits C, Greenberg S, Gregson B, Gress D, Gu E, Gupta G, Hall C, Harnof S, Hernandez F, Hoesch R, Hoh B, Houser J, Hu R, Huang J, Huang Y, Hussain M, Insinga S, Jadhav A, Jaffe J, Jahromi B, Jallo J, James M, James R, Janis S, Jankowitz B, Jeon E, Jichici D, Jonczak K, Jonker B, Karlen N, Kase C, Keric N, Kerz T, Kitagawa R, Knopman J, Koenig C, Krishnamurthy S, Kumar A, Kureshi I, Laidlaw J, Lakhanpal A, Latorre J, LeDoux D, Lees K, Leifer D, Leiphart J, Lenington S, Li Y, Lopez G, Lovick D, Lumenta C, Luo J, Maas M, MacDonald J, MacKenzie L, Madan V, Majkowski R, Major O, Malhorta R, Malkoff M, Mangat H, Maswadeh A, Matouk C, Mayo S, McArthur K, McCaul S, Medow J, Mezey G, Mighty J, Miller D, Mitchell P, Mohan K, Mould W, Muir K, Muñoz L, Nakaji P, Nee A, Nekoovaght-Tak S, Nyquist P, O'Kane R, Okasha M, O'Kelly C, Ostapkovich N, Pandey A, Parry-Jones A, Patel H, Perla K, Pollack A, Pouratian N, Quinn T, Rajajee V, Reddy K, Rehman M, Reimer R, Rincon F, Rosenblum M, Rybinnik I, Sanchez B, Sansing L, Sarabia R, Schneck M, Schuerer L, Schul D, Schweitzer J, Seder D, Seyfried D, Sheth K, Spiotta A, Stechison M, Sugar E, Szabo K, Tamayo G, Tanczos K, Taussky P, Teitelbaum J, Terry J, Testai F, Thomas K, Thompson C, Thompson G, Torner J, Tran H, Tucker K, Ullman N, Ungar L, Unterberg A, Varelas P, Vargas N, Vatter H, Venkatasubramanian C, Vermillion K, Vespa P, Vollmer D, Wang W, Wang Y, Wang Y, Wen J, Whitworth L, Willis B, Wilson A, Wolfe S, Wrencher M, Wright S, Xu Y, Yanase L, Yenokyan G, Yi X, Yu Z, Zomorodi A. Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery 2019, 84: nyz077-. PMID: 30891610, PMCID: PMC6537634, DOI: 10.1093/neuros/nyz077.Peer-Reviewed Original ResearchConceptsRecombinant tissue plasminogen activatorTissue plasminogen activatorICH volumeImproved mortalityIntracerebral hemorrhageFunctional outcomePlasminogen activatorFunctional outcome benefitsInitial hematoma volumeHistory of hypertensionBenefits of surgeryType of strokeDisease severity factorsSurgical performanceVolume reductionAlteplase dosesMRS 0Mortality benefitPrimary outcomeHematoma evacuationCatheter aspirationHematoma volumeICH evacuationOutcome benefitsSurgical arm
2009
Who will participate in acute stroke trials?
Kasner SE, Del Giudice A, Rosenberg S, Sheen M, Luciano JM, Cucchiara BL, Messé S, Sansing LH, Baren JM. Who will participate in acute stroke trials? Neurology 2009, 72: 1682-1688. PMID: 19433742, PMCID: PMC2683644, DOI: 10.1212/wnl.0b013e3181a55fbe.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAttitude to HealthBiomedical ResearchCaregiversClinical Trials as TopicCultureData CollectionFemaleHumansInformed ConsentMaleMental CompetencyMiddle AgedPatient CompliancePatient Education as TopicPhysician-Patient RelationsProspective StudiesRisk AssessmentRisk-TakingStrokeConceptsAcute treatment trialsAcute strokeTreatment trialsClinical trialsAcute stroke treatment trialsAcute stroke clinical trialsMean age 63Stroke treatment trialsVascular risk factorsMinority of patientsAcute stroke trialsStroke clinical trialsNovel therapeutic agentsStroke severityClinical factorsPrimary outcomeStroke trialsAcute trialProspective surveyTrial interventionRisk factorsStroke typeHigh incidenceAge 63Patients